Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tekmira Pharmaceuticals, a biopharmaceutical company, has expanded its executive management team with the addition of two key individuals to support the company's growth. Tekmira has appointed Tammy Mullarky as vice president of strategic planning and business development and Peter Lutwyche as vice president of pharmaceutical development.
Subscribe to our email newsletter
Ms Mullarky has joined Tekmira effective immediately and will have responsibility for strategic planning and business development including securing additional licensing and collaborative R&D agreements for Tekmira’s technology.
Dr Lutwyche joined Tekmira’s subsidiary company, Protiva Biotherapeutics, in February 2008, and has responsibility for manufacturing, process development and quality control for all Tekmira product candidates as well as supporting Tekmira’s collaborative partners as they advance products based on Tekmira’s technology.
Mark Murray, president and CEO of Tekmira, said: “We are extremely pleased to add Tammy and Peter to our executive management team as each bring significant experience in their respective fields. These appointments further support our corporate priorities of advancing proprietary siRNA product candidates and licensing our leading RNAi technology to the pharmaceutical industry.”